Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
Treatment Location: N/A
Primary: Response rate (complete remission (CR) conversion to minimal residual disease (MRD) negative, partial remission (PR) conversion to nodular partial remission nPR or CR, and nPR conversion to complete remission (CR) with ofatumumab treatment in patients with residual disease. Secondary: Determine the time-to-treatment failure and progression-free survival. Determine the time-to-next chronic lymphocytic leukemia (CLL) treatment after ofatumumab Evaluate the safety and tolerability of ofatumumab for residual disease. Evaluate the pharmacokinetics of ofatumumab in this trial for residual disease and in maintenance.
IRB Review and Approval Date: 07/06/2011
Recruitment Status: Closed
Projected Accrual: N/A